Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Seikagaku
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Dry Eye Disease|Dry Eye Syndromes|Keratoconjunctivitis Sicca
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05411367 |
SIDE | P3 |
Completed |
Dry Eye Disease|Keratoconjunctivitis Sicca|Dry Eye Syndromes |
2023-03-02 |
10% |
2023-05-22 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|